Sobi share new clinical data across multiple hematologic diseases at EHA 2025
STOCKHOLM, June 12, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) will present data at the 30th EHA (European Haematology Association) hybrid congress, in Milan, Italy (12-15 June). The congress will feature the latest advances in the treatment of diffuse large B-cell lymphoma (DLBCL), immune thrombocytopenia (ITP), myelofibrosis, paroxysmal nocturnal haemoglobinuria (PNH), and primary hemophagocytic lymphohistiocytosis (pHLH).
An extensive programme of poster presentations will showcase Sobi's commitment to helping patients with rare diseases by advancing treatment options. In addition, Sobi will host several scientific symposiums at the congress including:
"The breadth of data that we share at this year's EHA congress demonstrates Sobi's comprehensive approach to addressing rare conditions in haematology. We are proud to contribute to advancing the science in several indications from early clinical phases in diffuse large B-cell lymphoma to clinical and real-world evidence in myelofibrosis, primary hemophagocytic lymphohistiocytosis, immune thrombocytopenia and paroxysmal nocturnal haemoglobinuria," said Lydia Abad-Franch, MD, Head of R&D and Medical Affairs, and Chief Medical Officer at Sobi.
Key data to be presented at EHA 2025
DLBCL | |
PS1911: Initial Results From LOTIS-7: A Phase 1b Study of Loncastuximab Tesirine Plus Glofitamab in | Poster presentation Session title: Poster Session 2 Session time: 18:30-19:30 CEST Location: Poster Hall
|
PS1957: Updated Safety Run-in Results from LOTIS-5: A Phase 3, Randomized Trial of Loncastuximab Presenting Author: Carmelo Carlo-Stella | |
Immune Thrombocytopenia (ITP) | |
PF1236: Platelet Response to Avatrombopag Among Patients with Primary Immune Presenting Author: Shruti Chaturvedi |
Poster presentation Session title: Poster Session 1 Session time: 18:30 - 19:30 CEST Location: Poster Hall |
PF1239: Durability of Response to Avatrombopag Among Patients with Primary Immune Presenting Author: Srikanth Nagalla | |
PF1251: Clinically Meaningful Response to Avatrombopag: A Phase 3B Trial for Treatment of Children Presenting Author: Rachael F. Grace | |
PS2231: Effectiveness and safety of avatrombopag for the treatment of adults with newly diagnosed, Presenting Author: Waleed Ghanima |
Poster presentation Session title: Poster Session 2 Session time: 18:30 - 19:30 CEST Location: Poster Hall |
PS2234: Efficacy and safety of avatrombopag for the treatment of pediatric immune Presenting Author: Rachael F. Grace | |
PS2239: Real-World Treatment Patterns & Clinical Outcomes in Thrombopoietin Receptor Agonist Presenting Author: Sandhya Panch | |
PS2242: Effectiveness and safety of avatrombopag for treatment of immune thrombocytopenia in Presenting Author: María Eva Mingot-Castellano | |
PS2244: Response to Avatrombopag Among Patients with Chronic and Persistent Primary Immune Presenting Author: M Y Levy | |
PS2250: Evaluation of Efficacy and Safety of Avatrombopag in Children with Immune Presenting Author: Rachael F. Grace | |
PB3676: Baseline Correlates with Durability of Avatrombopag Response: A Phase 3B Trial for |
Publication Only Published on May 14 at 15:30 CEST |
PB3684: Consistent Response to Avatrombopag across Various Baseline Characteristics: Results from | |
Myelofibrosis | |
PF849: Hematologic improvement experienced by pacritinib-treated patients with myelofibrosis in Presenting Author: Michael Marrone | Poster presentation Session title: Poster Session 1 Session time: 18:30 - 19:30 CEST Location: Poster Hall |
PF1242: Efficacy of pacritinib vs momelotinib in patients with thrombocytopenic MF: a matched Presenting Author: Koo Wilson | |
PF1306: Transfusion-related cost and time burden offsets in patients with myelofibrosis treated with Presenting Author: Abiola Oladapo | |
PS1827: Real-world effectiveness of pacritinib in patients with myelofibrosis who have concurrent Presenting Author: Raajit Rampal | Poster presentation Session title: Poster Session 2 Session date: Saturday, 14 June Session time: 18:30-19:30 CEST Location: Poster Hall |
PS1842: Real-World Treatment Patterns and Clinical Outcomes in Patients with Myelofibrosis Treated Presenting Author: Doug Tremblay | |
PS2295: Economic Burden of Cytopenia in Patients with Myelofibrosis: Analysis of a US National Presenting Author: Lucia Marasova | |
PB3079: Cytopenia is associated with real-world disease progression and diminished survival in | Publication Only Published on May 14 at 15:30 CEST
|
Paroxysmal Nocturnal Hemoglobinuria | |
PF672: Early response in complement inhibitor naïve patients with paroxysmal nocturnal Presenting Author: Austin Kulasekararaj | Poster presentation Session title: Poster Session 1 Session time: 18:30 - 19:30 CEST Location: Poster Hall |
PF676: Interim analysis of the ongoing COMPLETE study on the real-world effectiveness of Presenting Author: Regis Peffault de Latour | |
PS1662: A benefit assessment of pegcetacoplan dose increase in the Phase 3 PEGASUS trial of PNH Presenting Author: Morag Griffin | Poster presentation Session title: Poster Session 2 Session time: 18:30 - 19:30 CEST Location: Poster Hall
|
PS1665: Benefit of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria irrespective Presenting Author: Britta Höchsmann | |
Primary Hemophagocytic Lymphohistiocytosis (pHLH) | |
PF1036: Emapalumab in patients with primary hemophagocytic lymphohistiocytosis: Efficacy and Presenting Author: Franco Locatelli | Poster presentation Session title: Poster Session 1 Session time: 18:30 - 19:30 CEST Location: Poster Hall |
About pegcetacoplan in rare diseases
Pegcetacoplan is a targeted C3 therapy designed to regulate excessive activation of the complement cascade, a part of the body's immune system, which can lead to the onset and progression of many serious diseases. Pegcetacoplan is under investigation for rare diseases across haematology and nephrology. Pegcetacoplan is approved for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) as EMPAVELI®/Aspaveli® in the United States, European Union, and other countries globally.
About Doptelet® (avatrombopag)
Doptelet® (avatrombopag) is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments, and a treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo an invasive procedure.
About Zynlonta® (loncastuximab tesirine)
Zynlonta® (loncastuximab tesirine) is a CD19-directed antibody drug conjugate (ADC). Zynlonta as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy.
About Sobi®
Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO: SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.
Contacts
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.
This information was brought to you by Cision http://news.cision.com.
The following files are available for download:
Sobi to share new clinical data across multiple hematologic diseases at EHA2025 |
View original content:https://www.prnewswire.co.uk/news-releases/sobi-share-new-clinical-data-across-multiple-hematologic-diseases-at-eha-2025-302480091.html